Outcome of SARS CoV-2 inpatients treated with convalescent plasma: One-year of data from the Veneto region (Italy) Registry
Randomized Controlled Trial
[키워드] absence
Administered
Admission
adverse event
adverse events
age
anti-SARS-CoV-2 antibody
Antibody titre
Arterial hypertension
Cancer
cardiovascular disease
CCP
CCP administration
CCP therapy
chest CT scan
chest X-ray
Chronic kidney disease
Comorbidity
condition
consolidation
contribute
convalescent
convalescent plasma
COVID-19
COVID-19 patient
Data analysis
death
Deceased
disease
drug
early treatment
Elderly patient
enrolled
Factor
Follow-up
fraction
Frequency
greater
hospital
Hospitalization
hospitalized patients
Inclusion
inclusion criteria
Inpatient
intensive care unit
interstitial
Italy
life-threatening
lung involvement
mechanical ventilation
Mortality
Neutralizing
neutralizing antibody
objective
Older age
outcome
overcome
oxygen
oxygen saturation
Oxygen therapy
PaO
Patient
patients treated
patients with COVID-19
plasma
Primary outcome
Prognosis
progression
radiological
randomized controlled study
reduced
registry
respiratory rate
SARS CoV-2
SARS-CoV-2
SARS-COV-2 infection
severe COVID-19
shown
significantly
tachypnea
TFS
therapeutic
titre
transfused
treated
Treatment
Veneto
Veneto region.
were recorded
[DOI] 10.1016/j.ejim.2021.12.023 PMC 바로가기 [Article Type] Randomized Controlled Trial
[DOI] 10.1016/j.ejim.2021.12.023 PMC 바로가기 [Article Type] Randomized Controlled Trial